FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034850147> ?p ?o ?g. }

• W3034850147 endingPage "1871" @default.
• W3034850147 startingPage "1862" @default.
• W3034850147 abstract "Background Overexpression of apurinic/apyrimidinic endonuclease 1 (APE1) is an important cause of poor chemotherapeutic efficacy in advanced non-small cell lung cancer (NSCLC) patients. Gossypol, a new inhibitor of APE1, in combination with docetaxel and cisplatin is believed to improve the efficacy of chemotherapy for advanced NSCLC with high APE1 expression. Methods Sixty-two patients were randomly assigned to two groups. Thirty-one patients in the experimental group received 75 mg/m2 docetaxel and 75 mg/m2 cisplatin on day 1 with gossypol administered at 20 mg once daily on days 1 to 14 every 21 days. The control group received placebo with the same docetaxel and cisplatin regimen. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), response rate, and toxicity. Results There were no significant differences in PFS and OS between the experimental group and the control group. The median PFS (mPFS) in the experimental and control groups was 7.43 and 4.9 months, respectively (HR = 0.54; p = 0.06), and the median OS (mOS) was 18.37 and 14.7 months, respectively (HR = 0.68; p = 0.27). No significant differences in response rate and serious adverse events were found between the groups. Conclusion The experimental group had a better mPFS and mOS than did the control group, though no significant difference was observed. Because the regimen of gossypol combined with docetaxel and cisplatin was well tolerated, future studies with larger sample sizes should be performed." @default.
• W3034850147 created "2020-06-19" @default.
• W3034850147 creator A5009211117 @default.
• W3034850147 creator A5009714134 @default.
• W3034850147 creator A5012339079 @default.
• W3034850147 creator A5012804068 @default.
• W3034850147 creator A5027984206 @default.
• W3034850147 creator A5046454314 @default.
• W3034850147 creator A5058094308 @default.
• W3034850147 creator A5060020861 @default.
• W3034850147 creator A5064478014 @default.
• W3034850147 creator A5066599847 @default.
• W3034850147 creator A5068523570 @default.
• W3034850147 creator A5068819007 @default.
• W3034850147 creator A5069130770 @default.
• W3034850147 date "2020-06-11" @default.
• W3034850147 modified "2023-09-22" @default.
• W3034850147 title "A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1" @default.
• W3034850147 cites W1487591931 @default.
• W3034850147 cites W1966033046 @default.
• W3034850147 cites W1976108799 @default.
• W3034850147 cites W1984054872 @default.
• W3034850147 cites W1987456989 @default.
• W3034850147 cites W1989340629 @default.
• W3034850147 cites W1994750661 @default.
• W3034850147 cites W2010563635 @default.
• W3034850147 cites W2012033459 @default.
• W3034850147 cites W2014788649 @default.
• W3034850147 cites W2020241378 @default.
• W3034850147 cites W2024889065 @default.
• W3034850147 cites W2040604770 @default.
• W3034850147 cites W2045519523 @default.
• W3034850147 cites W2052475175 @default.
• W3034850147 cites W2052908721 @default.
• W3034850147 cites W2054727327 @default.
• W3034850147 cites W2076285125 @default.
• W3034850147 cites W2076619368 @default.
• W3034850147 cites W2077364468 @default.
• W3034850147 cites W2085063683 @default.
• W3034850147 cites W2087369364 @default.
• W3034850147 cites W2096136751 @default.
• W3034850147 cites W2101995865 @default.
• W3034850147 cites W2113953529 @default.
• W3034850147 cites W2119107697 @default.
• W3034850147 cites W2119584322 @default.
• W3034850147 cites W2133028463 @default.
• W3034850147 cites W2137189203 @default.
• W3034850147 cites W2137249683 @default.
• W3034850147 cites W2144465864 @default.
• W3034850147 cites W2145835533 @default.
• W3034850147 cites W2145848541 @default.
• W3034850147 cites W2153223436 @default.
• W3034850147 cites W2159515687 @default.
• W3034850147 cites W2162724777 @default.
• W3034850147 cites W2163882233 @default.
• W3034850147 cites W2166399931 @default.
• W3034850147 cites W2549008179 @default.
• W3034850147 cites W2593833301 @default.
• W3034850147 cites W2739093603 @default.
• W3034850147 cites W2754623901 @default.
• W3034850147 cites W2883774000 @default.
• W3034850147 cites W2897235390 @default.
• W3034850147 cites W2937766145 @default.
• W3034850147 cites W2961561331 @default.
• W3034850147 cites W2969669884 @default.
• W3034850147 cites W2980240818 @default.
• W3034850147 cites W312156527 @default.
• W3034850147 doi "https://doi.org/10.1007/s10637-020-00927-0" @default.
• W3034850147 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7575477" @default.
• W3034850147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32529467" @default.
• W3034850147 hasPublicationYear "2020" @default.
• W3034850147 type Work @default.
• W3034850147 sameAs 3034850147 @default.
• W3034850147 citedByCount "10" @default.
• W3034850147 countsByYear W30348501472021 @default.
• W3034850147 countsByYear W30348501472022 @default.
• W3034850147 countsByYear W30348501472023 @default.
• W3034850147 crossrefType "journal-article" @default.
• W3034850147 hasAuthorship W3034850147A5009211117 @default.
• W3034850147 hasAuthorship W3034850147A5009714134 @default.
• W3034850147 hasAuthorship W3034850147A5012339079 @default.
• W3034850147 hasAuthorship W3034850147A5012804068 @default.
• W3034850147 hasAuthorship W3034850147A5027984206 @default.
• W3034850147 hasAuthorship W3034850147A5046454314 @default.
• W3034850147 hasAuthorship W3034850147A5058094308 @default.
• W3034850147 hasAuthorship W3034850147A5060020861 @default.
• W3034850147 hasAuthorship W3034850147A5064478014 @default.
• W3034850147 hasAuthorship W3034850147A5066599847 @default.
• W3034850147 hasAuthorship W3034850147A5068523570 @default.
• W3034850147 hasAuthorship W3034850147A5068819007 @default.
• W3034850147 hasAuthorship W3034850147A5069130770 @default.
• W3034850147 hasBestOaLocation W30348501471 @default.
• W3034850147 hasConcept C126322002 @default.
• W3034850147 hasConcept C142724271 @default.
• W3034850147 hasConcept C143998085 @default.
• W3034850147 hasConcept C197934379 @default.
• W3034850147 hasConcept C204787440 @default.
• W3034850147 hasConcept C27081682 @default.

• next